News Between Reporter

Bleecker Street has announced that it is extending the theatrical run of Waitress: The Musical due to its exceptional performance and sellouts nationwide. Originally planned for only a one-week run, the film adaptation of the enormously popular musical hit 1,214 screens across the United States and Canada last weekend. The film grossed an impressive $3.5
0 Comments
In a groundbreaking move, Shohei Ohtani has signed a historic contract with the Los Angeles Dodgers that will see him defer a staggering $68 million of his annual $70 million salary. This unprecedented arrangement significantly lowers the Dodgers’ payroll and potential tax burden, allowing them more flexibility in signing other players. Ohtani’s 10-year, $700 million
0 Comments
India’s stock market has achieved a significant milestone, surpassing Hong Kong to become the seventh largest stock market in the world. This achievement reflects growing optimism about India’s economic prospects and signals a shift in the global investment landscape. As of the end of November, the National Stock Exchange of India recorded a total market
0 Comments
Actor Zachary Levi, renowned for his portrayal of the superhero Shazam, recently expressed his enthusiasm to continue his journey in the Shazam! franchise. Despite the mixed reception of the forthcoming sequel, Fury of the Gods, Levi remains eager to delve further into the character’s narrative. In an interview with Comicbook.com, he exclaims, “I would love
0 Comments
Microsoft made a significant announcement on Monday, unveiling a groundbreaking partnership between the tech giant and the American Federation of Labor and Congress of Industrial Organizations (AFL-CIO). This strategic collaboration aims to initiate an open dialogue around the future of artificial intelligence (AI) and allay concerns regarding job displacement. With 60 unions and a staggering
0 Comments
Axatilimab, an investigational monoclonal antibody, has demonstrated promising results in the treatment of recurrent/refractory chronic graft-versus-host disease (cGVHD), according to findings from the phase II AGAVE-201 trial. These results, presented at the American Society of Hematology annual meeting by Daniel Wolff, MD, PhD, indicate that axatilimab achieved rapid and durable responses in patients with cGVHD.
0 Comments